Document:

Unassociated Document

    Exhibit
10.1

     

    
      FIFTH
AMENDMENT TO REGISTRATION RIGHTS AGREEMENT

      

      THIS FIFTH AMENDMENT (the “Amendment”)
is made as of December 21, 2009, to the Registration Rights Agreement (the
“Agreement”) between Neoprobe Corporation (the “Company”) and Platinum-Montaur
Life Sciences, LLC (the “Purchaser”), dated December 26, 2007, as amended by the
Amendment to Registration Rights Agreement, dated February 7, 2008, Second
Amendment to Registration Rights Agreement dated April 16, 2008, Third Amendment
to Registration Rights Agreement, dated July 10, 2008, and Fourth Amendment to
Registration Rights Agreement, dated December 5, 2008.  Capitalized
terms not otherwise defined herein shall have the meanings defined in the
Agreement.

      

      Recital

      

      The Company and the Purchaser desire to
amend certain provisions of the Agreement to modify the description of the
Registrable Securities as to which the Company is required to file a
registration statement.

      

      Statement of
Agreement

      

      In consideration of the foregoing, and
of their mutual promises contained herein, the parties agree as
follows:

      

      1.    Resale
Registration.  The first sentence of Section 2(a) of the
Agreement which originally stated that “On or prior to the Filing Date the
Company shall prepare and file with the Commission a “resale” Registration
Statement providing for the resale of all Registrable Securities for an offering
to be made on a continuous basis pursuant to Rule 415,” shall be deleted in its
entirety and replaced with the following: “On or prior to December 31, 2009, the
Company shall prepare and file with the Commission: (a) a post-effective
amendment to the registration statement on Form S-1 (file no. 333-150650) filed
by the Company on May 5, 2008, providing for the de-registration of the shares
of Common Stock registered thereby; and (b) a new “resale” registration
statement which shall provide for the resale of (i) up to 3,600,000 shares of
Common Stock issuable upon the conversion of a portion of the Company’s Amended
and Restated 10% Series A Convertible Senior Secured Promissory Note in the
principal amount of $7,000,000, due December 26, 2011 (the “Amended Series A
Note”), (ii) 6,000,000 shares of Common Stock issued upon exercise of the
Company’s Amended and Restated Series Y Warrant to purchase 6,000,000 shares of
Common Stock at an exercise price of $0.575 per share issued to the Purchaser
(the “Amended Series Y Warrant”), (iii) 3,500,000 shares of Common Stock
issuable as interest or dividends on the Amended Series A Note, the Company’s
Amended and Restated 10% Series B Convertible Senior Secured Promissory Note in
the principal amount of $3,000,000, due December 26, 2011 (the “Amended Series B
Note”), and 3,000 shares of the Company’s 8% Series A Cumulative Convertible
Preferred Stock issued to the Purchaser (the “Preferred Stock”), and (iv)
2,400,000 shares of Common Stock issuable upon exercise of the Company’s Series
AA Warrant to purchase 2,400,000 shares of Common Stock at an exercise price of
$0.97 per share issued to the Purchaser (the “Series AA Warrant”), provided that
the total number of shares of Common Stock registered does not exceed
15,500,000, for an offering to be made on a continuous basis pursuant to Rule
415. Additionally, within thirty-five (35) days of receipt from the Purchaser of
written request therefor, the Company shall prepare and file with the Commission
an additional “resale” registration statement providing for the resale of (i)
the remaining shares of Common Stock issuable upon the conversion of the Amended
Series A Note, (ii) the shares of Common Stock issuable upon the exercise of the
Amended Series W Warrant to purchase 6,000,000 shares of Common Stock at an
exercise price of $0.32 per share issued to the Purchaser, (iii) the shares of
Common Stock issuable upon the conversion of the Amended Series B Note, (iv) the
shares of Common Stock issuable upon the exercise of the Amended and Restated
Series X Warrant to purchase 8,333,333 shares of Common Stock at an exercise
price of $0.46 per share issued to the Purchaser, and (v) the shares of Common
Stock issuable upon conversion of the Preferred Stock, provided, however, that
the Company is not required to file such additional registration statement, or
may exclude shares from such additional registration statement, if it believes
in good faith, based upon advice from the Commission, that application of Rule
415 would not permit registration of all or the excluded portion of such shares
of Common Stock.

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      2.    Sole
Holder.  Purchaser represents that it has not assigned or
otherwise transferred any of the Registrable Securities entitled to registration
rights hereunder, and that as of the date of this Amendment, it is the sole
Holder of the Registrable Securities.

      

      3.    No Other
Modification.  Except as expressly modified or amended hereby,
the terms and conditions of the Agreement shall remain unchanged and in full
force and effect, and each of the parties hereby ratifies and confirms the same.
In the event of any conflict between the terms of the Agreement or any previous
amendment to the Agreement and this Amendment, the terms of this Amendment shall
govern.

      

      4.    Counterparts.  This
Amendment may be executed in counterparts, each of which shall be deemed to be
an original and all such counterparts together shall constitute one and the same
instrument.

      

      IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly
executed by their respective authorized persons as of the date first indicated
above.

       

      
        	 	      
                NEOPROBE
      CORPORATION

                

                

                By: /s/ Brent L.
      Larson

                  Name: Brent L.
      Larson

                  Title:
      Vice-President, Finance, Chief Financial Officer

                      Treasurer and
      Secretary

                      

                

                PLATINUM-MONTAUR
      LIFE SCIENCES, LLC

                 

                By: /s/ Michael
      Goldberg

                  Name: Michael
      Goldberg

                  Title: Portfolio
      Manager

              

      

       

       

      
        
           

        

        
          2Exhibit 10.1

     

    Confidential
Treatment Requested

     

    PUBLIC
HEALTH SERVICE

     

    SIXTH AMENDMENT TO
L-354-1998/0

     

    This is
the sixth amendment ("Sixth
Amendment") of the agreement by and between the National Institutes of
Health ("NIH") or the
Food and Drug Administration ("FDA"), hereinafter singly or
collectively referred to as agencies of the United States Public Health Service
("PHS") within the
Department of Health and Human Services ("HHS"), and Zonagen, Inc.
having an effective date of April 16,1999, and having NIH Reference Number
L-354-1998/0 ("Agreement").  This Sixth Amendment, having NIH Reference Number
L-354-1998/6, is made between the PHS through the Office of
Technology Transfer,
NIH, having an address at 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804, U.S.A., and Repros Therapeutics, Inc., having an
office at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas 77280
("Licensee").  This Sixth Amendment includes, in
addition to the amendments made below, 1) a Signature Page and 2) Attachment 1
(Royalty Payment Information).

     

    WHEREAS, PHS and Licensee desire that the Agreement be amended a sixth
time as set forth below in order to change its Appendix B-Licensed
Fields-of-Use and Licensed Territory, Appendix C—Royalties, and
Appendix E-Benchmarks and Performance.

     

    NOW,
THEREFORE, in consideration of the mutual covenants and promises contained
herein, PHS and Licensee, intending to be
bound, hereby mutually agree to the following:

     

    
      	
              1) 

            	
              Replace
      Appendix B in theAgreement, as amended,
      with Appendix B as follows:

            

    

     

    Licensed
Fields-of-Use:  Treatment of human endocrinologic pathologies
or conditions in steroid-sensitive tissues, including cancers related to the
human reproductive system.

     

    Licensed Territory:
Worldwide.

     

    
      	
              2) 

            	
              Replace
      Appendix C, I.) (ii) c through g with the
  following:

            

    

     

    
      	
               
      

            	
              c.

            	
              [**]
      within thirty(30) days of filing the first New Drug Application for a
      Licensed Product
      with the United States FDA.

            

    

     

    
      	
               
      

            	
              d.

            	
              [**]
      within thirty(30) days of filing the first new drug application for a
      Licensed Product
      with the appropriate agency or regulatory body of any European
      country.

            

    

     

    
      	
               
      

            	
              e.

            	
              [**]
      within thirty(30) days of filing the first new drug application for a
      Licensed Product
      with the appropriate Agency or regulatory body in
  Japan.

            

    

     

    
      	
               
      

            	
              f.

            	
              [**]
      within thirty (30) days of receipt of the first marketing approval for a
      Licensed Product
      from the United States FDA.

            

    

     

    
      	
               
      

            	
              g.

            	
              [**]
      within thirty (30) days of receipt of the first marketing approval for a
      Licensed Product
      from the appropriate agency or regulatory body of any European
      country.

            

    

     

    
      	
               
      

            	
              h.

            	
              [**]
      within thirty (30) days of receipt of the first marketing approval for a
      Licensed Product
      from the appropriate agency or regulatory body in
  Japan.

            

    

     

    
      
        
          
            
              	
                      A-285-2009

                    	 
      	
                      CONFIDENTIAL

                    
	
                      Sixth
      Amendment of L-354-1998/0

                    	
                      Final
      REPROS THERAPEUTICS, INC.

                    	
                      July
      7, 2009

                    
	
                      Model
      09-2006 (updated 3-2009)

                    	
                      Page
      1 of 5

                    	
                      L-354-1998/6

                    

            

          

        

      

      

      __________________

      Portions
of this Exhibit have been omitted pursuant to a request for confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended, and Rule 406 under the Securities Act of 1933, as amended.
These omitted portions have been marked with "**" and have been filed separately
with the Securities and Exchange Commission.

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
       

      SIXTH AMENDMENT TO
L-354-1998/0

       

    

    
      	
              3)

            	
              Replace
      Appendix E in the Agreement, as amended, with Appendix E as
      follows:

            

    

     

    Licensee agrees to the
following Benchmarks for
the purpose of measuring its performance under this Agreement.
Licensee  shall notify  PHS  in
writing within thirty (30) days of achieving all such  Benchmarks.  They
are as follows:

     

    
      
        
          
            	 
      	
                    Benchmark

                  	 
      	
                    Date

                  
	
                    1.

                  	
                    Obtain
      financing, upfront licensing consideration, or any combination thereof
      (all of which are subject to section 1(vi) of Appendix C of
      this  Agreement ) of no less than a combined total of Six
      Million Dollars ($6,000,000)

                  	 
      	
                    9/30/2009

                  
	
                    2.

                  	
                    File
      NDA in U.S. for first indication

                  	 
      	
                    06/30/2011

                  
	
                    3.

                  	
                    File
      for approval of Licensed
      Product in Europe for first indication

                  	 
      	
                    [**]

                  
	
                    4.

                  	
                    File
      for approval of Licensed
      Product in Japan for first indication

                  	 
      	
                    [**]

                  
	
                    5.

                  	
                    Initiate
      Phase III clinical trial in U.S. for second indication

                  	 
      	
                    Completed

                  
	
                    6.

                  	
                    Initiate
      Phase III clinical trial in Europe for second indication

                  	 
      	
                    [**]

                  
	
                    7.

                  	
                    Initiate
      Phase III clinical trial in Japan for second indication

                  	 
      	
                    [**]

                  
	
                    8.

                  	
                    File
      NDA in U.S. for second indication

                  	 
      	
                    [**]

                  
	
                    9.

                  	
                    File
      for approval of Licensed
      Product in Europe for second indication

                  	 
      	
                    [**]

                  
	
                    10.

                  	
                    File
      for approval of Licensed
      Product in Japan for second indication

                  	 
      	
                    [**]

                  

          

        

      

    

     

    
      	
              4)

            	
              Within
      thirty (30) days of the execution of this Sixth Amendment, Licensee shall pay PHS an amendment issue
      royalty in the sum of One Hundred Thousand US Dollars ($100,000), to be
      sent to the address specified in Attachment
1.

            

    

     

    
      	
              5)

            	
              In
      the event any provision(s) of the Agreement is/are
      inconsistent with Attachment 1, such provision(s) is/are hereby amended to
      the extent required to avoid such inconsistency and to give effect to the
      shipping and payment information in such Attachment
  1.

            

    

     

    
      	
              6)

            	
              All
      terms and conditions of the Agreement not herein
      amended remain binding and in
effect.

            

    

     

    
      	
              7)

            	
              The
      terms and conditions of this Amendment shall, at
      PHS' sole option,
      be considered by PHS to be withdrawn from
      Licensee's
      consideration and the terms and conditions of this Amendment, and the Amendment itself to be
      null and void, unless this Amendment is executed by
      the Licensee and a
      fully executed original is received by PHS within sixty (60)
      days from the date of PHS signature found at
      the Signature Page.

            

    

     

    
      	
              8)

            	
              This
      Sixth Amendment is
      effective upon execution by all
parties.

            

    

     

     

    SIGNATURES
BEGIN ON NEXT PAGE

     

     

    
      	
              A-285-2009

            	 
      	
              CONFIDENTIAL

            
	
              Sixth
      Amendment of L-354-1998/0

            	
              Final
      REPROS THERAPEUTICS, INC.

            	
              July
      7, 2009

            
	
              Model
      09-2006 (updated 3-2009)

            	
              Page 2
      of 5

            	
              L-354-1998/6

            

      

      __________________

      Portions
of this Exhibit have been omitted pursuant to a request for confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended, and Rule 406 under the Securities Act of 1933, as amended.
These omitted portions have been marked with "**" and have been filed separately
with the Securities and Exchange Commission.

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    SIGNATURE
PAGE

     

    In
Witness Whereof, the parties have executed this Sixth Amendment on the dates
set forth, below. Any communication or notice to be given shall be forwarded to
the respective addresses listed below.

     

    
      
        
          	
                  For
      PHS:

                   

                  /s/  Mark L.
      Rohrbaugh

                  Mark
      L. Rohrbaugh, Ph.D., J.D.

                  Director

                  Office
      of Technology Transfer

                  National
      Institutes of Health

                   

                  Mailing
      Address for Agreement
      notices:

                  Chief,
      Monitoring & Enforcement Branch, DTDT

                  Office
      of Technology Transfer

                  National
      Institutes of Health

                  6011
      Executive Boulevard, Suite 325

                  Rockville,
      Maryland 20852-3804 U.S.A.

                	
                   

                   

                  7/7/09

                  Date

                
	 
      	 
      

        

      

    

    For Licensee (Upon, information
and belief, the undersigned expressly certifies or affirms that the contents of
any statements of
Licensee made or referred to in this document are truthful and
accurate.):

     

    
      
        
          	
                  by:

                  /s/  Joseph S.
      Podolski

                  Joseph
      S. Podolski

                  Chief
      Executive Officer

                   

                  Official
      and Mailing Address for Agreement
      notices:

                  Joseph
      S. Podolski

                  Chief
      Executive Officer

                  Repros
      Therapeutics, Inc.

                  2408
      Timberloch Place

                  Suite
      B-7

                  The
      Woodlands, Texas 77380

                  Email
      Address:

                  Telephone:

                  Fax:

                	
                   

                  7/7/09

                  Date

                
	 
      	 
      

        

      

    

     

    
      	
              A-285-2009

            	 
      	
              CONFIDENTIAL

            
	
              Sixth
      Amendment of L-354-1998/0

            	
              Final
      REPROS THERAPEUTICS, INC.

            	
              July
      7, 2009

            
	
              Model
      09-2006 (updated 3-2009)

            	
              Page 3
      of 5

            	
              L-354-1998/6

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Official
and Mailing Address for Financial notices (Licensee's contact person
for royalty payments):

     

    Louis
Ploth

    CFO and
VP, Business Development

    Repros
Therapeutics, Inc.

    2408
Timberloch Place

    Suite B-7

    The
Woodlands, Texas 77380

    Email
Address:

    Telephone:

    Fax:

     

    Any false
or misleading statements made, presented, or submitted to the Government, including any
relevant omissions, under this
Agreement and during the course of negotiation of this Agreement are subject to all
applicable civil and criminal statutes including Federal statutes 31 U.S.C.
§§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability
including fine(s) or imprisonment).

     

     

    
      	
              A-285-2009

            	 
      	
              CONFIDENTIAL

            
	
              Sixth
      Amendment of L-354-1998/0

            	
              Final
      REPROS THERAPEUTICS, INC.

            	
              July
      7, 2009

            
	
              Model
      09-2006 (updated 3-2009)

            	
              Page 4
      of 5

            	
              L-354-1998/6

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ATTACHMENT 1 — ROYALTY
PAYMENT OPTIONS

     

    NIH/PHS License
Agreements

     

    *In order to process payment
via Electronic Funds Transfer sender MUST supply the following
information:

     

    Procedure
for Transfer of Electronic Funds to NIH for Royalty Payments

     

    Bank
Name:

     

    NOTE:  Only
U.S. banks can wire directly to the Federal Reserve Bank, Foreign banks cannot
wire directly to the Federal Reserve Bank, but must go through an intermediary
U.S. bank. Foreign banks may send the wire transfer to the U.S. bank of their
choice, who, in turn forwards the wire transfer to the Federal Reserve
Bank.

     

    Checks
drawn on a U.S. bank account should be sent directly to the following
address:

     

    National
Institutes of Health (NIH)

     

    Overnight
or courier deliveries should be sent to the following address:

     

    Checks
drawn on a foreign bank account should be sent directly to the following
address:

     

    National
Institutes of Health (NIH)

    Office of
Technology Transfer

    Royalties
Administration Unit

     

    All
checks should be made payable to "NIH Patent Licensing."

     

    The OTT Reference Number
MUST appear on checks, reports and correspondence

     

     

     

    
      	
              A-285-2009

            	 
      	
              CONFIDENTIAL

            
	
              Sixth
      Amendment of L-354-1998/0

            	
              Final
      REPROS THERAPEUTICS, INC.

            	
              July
      7, 2009

            
	
              Model
      09-2006 (updated 3-2009)

            	
              Page 5
      of 5

            	
              L-354-1998/6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]